Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model

Catheterization and Cardiovascular Interventions

Volumn 54, Issue 2, 2001, Pages 247-256

  Kipshidze, Nicholas ^a,f   Keane, Eamon ^b   Stein, David ^b   Chawla, Paramjith ^c   Skrinska, Victor ^c   Shankar, Latha Raja ^d   Khanna, Ashwani ^d   Komorowski, Richard ^e   Haudenschild, Christian ^e   Iversen, Patrick ^a   Leon, Martin B ^a   Keelan, Michael H ^b   Moses, Jeffrey ^a,e  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^d HOLLAND LABORATORY   (United States)

^e AVI BIOPHARMA INC   (United States)

^f LENOX HILL HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Angioplasty; Antisense; Local drug delivery; Restenosis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AVI 4126; CHOLESTEROL; EOSIN; FORMALDEHYDE; HEMATOXYLIN; MESSENGER RNA; MYC PROTEIN;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; HISTOLOGY; HUMAN; HUMAN CELL; ILIAC ARTERY; NONHUMAN; RABBIT; RESTENOSIS; SMOOTH MUSCLE FIBER; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CONSTRICTION, PATHOLOGIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GENES, MYC; HYPERPLASIA; ILIAC ARTERY; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDES, ANTISENSE; RABBITS; TIME FACTORS; TUNICA INTIMA;

EID: 0034792266     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.1277     Document Type: Article

References (49)

1. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen
2. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle proliferation in vitro
3. Frontiers in interventional cardiology
4. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy
5. Endovascular stents reduce restenosis by eliminating geometric arterial remodeling: A serial intravascular ultrasound study
6. Antisense c-myb oligonucleotides inhibit arterial smooth muscle cell accumulation in vivo
7. Single intraluminal delivery of antisense cdc2 kinase and proliferating cell nuclear antigen oligonucleotides result in chronic inhibition of neointimal hyperplasia
8. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
9. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides
10. c-myc in vasculoproliferative disease
11. Transcatheter delivery of c-myc antisense oligomers reduced neointimal formation in a porcine model of coronary artery balloon injury
12. Endoluminal local delivery of PCNA/cdc2 antisense oligonucleotides by porous balloon catheter does not affect neointima formation or vessel size in the pig coronary artery model of postangioplasty restenosis
13. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty
14. The PREVENT trial of vein graft genetic engineering: Preliminary molecular and clinical findings
15. Synthetic DNA-based compounds for the prevention of coronary restenosis: Current status and future challenges
16. Antisense oligonucleotide against c-myc administered with the Transport delivery catheter for the prevention of in-stent restenosis. Results of the randomized ITALICS trial
17. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?
18. Does antisense exist?
19. Fluorescence microscopic comparison of the binding of phosphodiester and phosphothioate oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum and the nuclear interior
20. Resistance of morpholine phosphorodiamidate oligomers to enzymatic degradation
21. A specificity comparison of four antisense types: Morpholine, 2′-O-methyl RNA, DNA, and phosphorothioate DNA
22. Morpholine and phosphorothioate antisense oligomers compared in cell-free and in-cell systems
23. In vivo efficacy of morpholine modified oligomers directed against tumor necrosis factor-α mRNA
24. Comparison of efficacy of antisense oligomers directed toward TNF-α in helper T and macrophage cell lines
25. Antisense morpholine oligonucleotide analog induces misplacing of c-myc mRNA
26. Morpholine antisense oligomers: Design, preparation and properties
27. A method for incorporating macromolecules into adherent cells
28. A simple method for delivering morpholine antisense oligos into the cytoplasm of cells
29. Sensitivity to transforming growth factor beta-1 induced growth arrest is common in human squamous cell carcinoma cell lines: c-myc down-regulation and p21 and Wat induction are important early events
30. Transforming growth factor beta 1 suppression of c-myc gene transcription: Role in inhibition of keratinocyte proliferation
31. c-myc and pRB role in TGF beta 1 inhibition of keratinocyte proliferation
32. Transforming growth factor beta 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes
33. Sequence independent effects of phosphorothiolated oligonucleotides on synaptic transmission and the excitability in the hippocampus in vivo
34. Cardiovascular effects of a phosphorothioate oligonucleotide sequence antisense to p 53 in the conscious rhesus monkey
35. Complement activation and dynamic changes following intravenous administration of phosphorothioate oligonucleotides in monkey
36. Evaluation of the toxicity of Isis 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomologus monkeys
37. Toxicity of oligonucleotide therapeutic agents
38. Single dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide after intravenous infusion of cynomolgus monkeys
39. Disposition of oligonucleotides in isolated perfused rat kidney; involvement of scavenger receptors in tier renal uptake
40. Co-administration of polyanions with phosphorothioate oligodeoxynucleotide (CGP 69846A); a role for the scavenger receptors in vivo disposition
41. A new approach for local intravascular drug delivery: Iontophoretic balloon
42. RNase H is responsible for non-sequence specific inhibition of in vitro translation by 2′-O-alkyl chimeric oligonucleotides: High affinity or selectivity, a dilemma to design antisense oligomers
43. Role of RNase H in the action of antisense oligonucleotides
44. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model
45. Reconstruction of balloon injured artery with fibrin glue/endothelial cell matrix
46. Therapeutic angiogenesis for critical limb ischemia to limit or avoid amputation
47. Balloon-artery interactions during stent placement: A finite element analysis approach to pressure, compliance, and stent design as contributors to vascular injury
48. Coronary restenosis: Prospects for solution and new perspectives from a porcine model